2016 | Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. | Hoang, JK; Yang, HI ; Le, A; Nguyen, NH; Lin, D; Vu, VD; Chaung, K; Nguyen, V; Trinh, HN; Li, J; Zhang, JQ; Chen, CJ ; Nguyen, MH | Medicine 95(31), e4433 | | | |
2020 | Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy. | Yang, HI ; Yeh, ML; Wong, GL; Peng, CY; Chen, CH; Trinh, HN; Cheung, KS; Xie, Q; Su, TH; Kozuka, R; Lee, DH; Ogawa, E; Zhao, C; Ning, HB; Huang, R; Li, J; Zhang, JQ; Ide, T; Xing, H; Iwane, S; Takahashi, H; Wong, C; Wong, C; Lin, CH; Hoang, J; le, A; Henry, L; Toyoda, H; Ueno, Y; Gane, EJ; Eguchi, Y; Kurosaki, M; Wu, C; Liu, C; Shang, J; Furusyo, N; Enomoto, M; Kao, JH; Yuen, MF; Yu, ML; Nguyen, MH | The Journal of infectious diseases 221(3), 389-399 | | | |
2016 | Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients. | Yang, HI ; Nguyen, N; Hoang, J; Kim, Y; Vu, V; Le, A; Chaung, K; Nguyen, V; Trinh, H; Li, J; Zhang, J; Hsing, A; Chen, CJ ; Nguyen, MH | Alimentary pharmacology & therapeutics 44(8), 846-855 | | | |